Triazole antifungal
Itraconazole
Inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and destabilizing the fungal membrane.
Primary Mechanism of Action
Clinical / Scientific
Itraconazole binds fungal lanosterol 14α-demethylase (CYP51), preventing conversion of lanosterol to ergosterol. Membrane sterol depletion and accumulation of methylated sterols impair membrane function in susceptible fungi. It is also a potent human .
Pathway Targets
CYP51 (lanosterol 14α-demethylase)
Scientific explanation
Blockade of ergosterol biosynthesis.
CYP3A4
Scientific explanation
Host inhibition relevant to drug–drug interactions, not antifungal efficacy.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Membrane sterol failure
Target to downstream effect: CYP51 inhibition → Ergosterol depletion → Fungal membrane dysfunction
Mechanistically Relevant Repurposed & Adjunctive Applications
Susceptible fungal infections
EstablishedMechanistic rationale
Established systemic azole for labelled susceptible mycoses.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| Fungal CYP51 | Inhibition | Ergosterol synthesis | Established mechanism |
| Human CYP3A4 | Inhibition | Pharmacokinetic interactions | Established mechanism |
Mechanistic Interaction Considerations
Strong inhibition creates many serious interaction risks (including some QT-prolonging and immunosuppressant drugs). Use labelled interaction tables; this page does not list a complete contraindication set.
In Plain Language
Itraconazole stops fungi from making ergosterol, the sterol they need in their membranes — similar to how humans need cholesterol in cell membranes.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
CYP51 (lanosterol 14α-demethylase)
Oncology Mechanistic Relevance
Cancers in the atlas where this compound has a mapped mechanistic rationale. Evidence tiers are not equivalent and do not imply treatment.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Hedgehog antagonism and anti-angiogenic endothelial reports exist, including early clinical probes. Not a licensed antineoplastic.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.